A record of what Milind Karmarkar said publicly, with the source. Not advice.
Pending — not yet graded
“Bullish on the Indian Pharma sector, despite global de-globalisation and tariff threats. He believes that while India is a large supplier to the United States, the US also depends on Indian pharma, suggesting there will be no significant tariff implications for the sector.”
Nifty PharmaBullishCalled 24 Feb 2025
This call has no verdict yet — it is graded HIT or MISS against real price data once a close decides it. Save it above to find it again from your profile.
Read the original articleSee Milind Karmarkar’s full track record